Mersana, Teva Pharmaceuticals Sign Agreement To Develop Anti-angiogenic Agent
Mersana plans to initiate a Phase 1 clinical trial for XMT-1107 in the second quarter of 2010. XMT-1107 is expected to be the company’s second oncology product to
The European Commission (EC) has granted orphan designation to Lundbeck’s investigational monoclonal antibody asedebart (Lu AG13909) for the treatment of Cushing’s syndrome of endogenous origin.
Under the terms of the three-year agreement, Premier members will continue to have access to specially negotiated pricing for automation, general chemistry, immunoassay and integrated work cell products
Biologics Process Developments has specialized in contract laboratory services in molecular biology, recombinant protein expression and purification, cell culture, bacterial fermentation, frozen cell/material storage, and consulting in biologics